[Local administration of an anabolic hormone in ophthalmology].
D000109:Acetylcholine / Q000627:therapeutic use; D000596:Amino Acids / Q000627:therapeutic use; D000758:Anesthesia / Q000009:adverse effects; D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D000891:Anti-Infective Agents, Local / Q000009:adverse effects; D001710:Biotin / Q000627:therapeutic use; D001803:Blood Transfusion; D002465:Cell Movement; D002734:Chlorophyll / Q000627:therapeutic use; D003315:Cornea / Q000187:drug effects*; D003348:Cortisone / Q000009:adverse effects; D003553:Cystine / Q000627:therapeutic use; D004848:Epithelium / Q000187:drug effects; D005126:Eye Burns / Q000188:drug therapy*; D005128:Eye Diseases / Q000188:drug therapy; D006493:Heparin / Q000627:therapeutic use; D006566:Herpesviridae Infections / Q000188:drug therapy; D006801:Humans; D007065:Idoxuridine / Q000009:adverse effects; D007634:Keratitis / Q000188:drug therapy*; D007637:Keratoconjunctivitis / Q000188:drug therapy; D007809:Lanolin / Q000009:adverse effects; D008696:Methandrostenolone / Q000008:administration & dosage*; D008938:Mitosis; D010205:Pantothenic Acid / Q000627:therapeutic use; D010592:Pharmaceutic Aids; D010924:Placental Extracts / Q000627:therapeutic use; D051381:Rats; D012038:Regeneration / Q000187:drug effects*; D013449:Sulfonamides / Q000009:adverse effects; D013696:Temperature; D014467:Ultraviolet Therapy / Q000009:adverse effects; D014801:Vitamin A / Q000627:therapeutic use
D000596:Amino Acids; D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D010592:Pharmaceutic Aids; D010924:Placental Extracts; D013449:Sulfonamides; D014801:Vitamin A; D002734:Chlorophyll; D010205:Pantothenic Acid; D003553:Cystine; D001710:Biotin; D007809:Lanolin; D006493:Heparin; D008696:Methandrostenolone; D007065:Idoxuridine; D000109:Acetylcholine; D003348:Cortisone
L'administration locale d'une hormone anabolique en ophtalmologie.